自噬
二甲双胍
炎症
生物能学
线粒体
细胞因子
粒体自噬
糖尿病
线粒体ROS
医学
细胞生物学
免疫学
生物
内分泌学
细胞凋亡
生物化学
作者
Leena P. Bharath,Manju Agrawal,Grace McCambridge,Dequina Nicholas,Hatice Hastürk,Jing Liu,Kai Jiang,Rui Li,Zhenheng Guo,Jude T. Deeney,Caroline M. Apovian,Jennifer Snyder‐Cappione,Gregory S. Hawk,Rebecca M. Fleeman,Riley Pihl,Katherine Thompson,Anna C. Belkina,Licong Cui,Elizabeth A. Proctor,Philip A. Kern,Barbara S. Nikolajczyk
出处
期刊:Cell Metabolism
[Elsevier]
日期:2020-07-01
卷期号:32 (1): 44-55.e6
被引量:321
标识
DOI:10.1016/j.cmet.2020.04.015
摘要
Age is a non-modifiable risk factor for the inflammation that underlies age-associated diseases; thus, anti-inflammaging drugs hold promise for increasing health span. Cytokine profiling and bioinformatic analyses showed that Th17 cytokine production differentiates CD4+ T cells from lean, normoglycemic older and younger subjects, and mimics a diabetes-associated Th17 profile. T cells from older compared to younger subjects also had defects in autophagy and mitochondrial bioenergetics that associate with redox imbalance. Metformin ameliorated the Th17 inflammaging profile by increasing autophagy and improving mitochondrial bioenergetics. By contrast, autophagy-targeting siRNA disrupted redox balance in T cells from young subjects and activated the Th17 profile by activating the Th17 master regulator, STAT3, which in turn bound IL-17A and F promoters. Mitophagy-targeting siRNA failed to activate the Th17 profile. We conclude that metformin improves autophagy and mitochondrial function largely in parallel to ameliorate a newly defined inflammaging profile that echoes inflammation in diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI